Reinholdt, K. http://orcid.org/0000-0003-4941-9665
Munk, C.
Thomsen, L. T. http://orcid.org/0000-0002-0738-8410
Dehlendorff, C. http://orcid.org/0000-0001-6161-4565
Carstensen, B. http://orcid.org/0000-0002-5161-2192
Jørgensen, M. E. http://orcid.org/0000-0001-8356-5565
Kjaer, S. K. http://orcid.org/0000-0002-8347-1398
Funding for this research was provided by:
MERMAID II
Article History
Received: 29 March 2021
Accepted: 11 August 2021
First Online: 9 September 2021
Declarations
:
: Dr. Kjær has received lectures fees from Merck and a research grant through her institution from Merck. Dr. Jørgensen has received research grants from Astra Zeneca, Sanofi Aventis, AMGEN, Boehringer Ingelheim, Novo Nordisk and holds shares in Novo Nordisk A/S. Dr. Carstensen holds shares in Novo Nordisk A/S and has received lecture and consultancy fees from Novo Nordisk and Leo Pharma. All other authors declare no potential conflicts of interest.
: The study was approved by the Danish Data Protection Agency (j. no. 2015–41-3740). Use of data from the Prescription Register was approved by the National Board of Health Data FSE-ID 3357).<b>Informed consent</b>According to Danish law, approvals from a Health Research Ethics Committee and informed consent are not required for register-based studies.